Sobi Works to Expand Rare Disease Indications for Its Drugs

Sobi is a drugmaker focused on hemophilia, inflammation, and genetic and metabolic diseases. It is now pursuing its drug Orfadin, used to treat the metabolic disorder tyrosemia type 1, as a potential treatment for the metabolic condition alkaptonuria. It is also pursuing Kineret, its drug for the rare inflammatory condition NOMID, as a potential therapy for Still’s disease. We spoke to Rami Levin, president of North America for Sobi, and Len Walt, vice president and head of medical affairs of North America for Sobi, about the company’s evolution, its growing pipeline, and its effort to expand indications for its rare disease drugs.